A bespoke solution to cell therapy manufacturing: the Cocoon platformPublished: September 16, 2019
September 26th 2019, 08:00 PST; 11:00 EST; 16:00 BST; 17:00 CEST
The Cocoon™ is a closed, automated, scalable platform for patient-scale cell therapy manufacturing. Through the Cocoon™ platform’s single-use, highly customizable cassette, we can tailor the platform to your process. Using in-process monitoring and cassette customization, The Cocoon platform provides increased control over cell therapy manufacturing processes.
- Basic Cocoon functionality
- How a cell therapy process is translated into the Cocoon
- Ways in which the Cocoon alleviates cell therapy manufacturing pain-points
- Process comparability to other cell therapy manufacturing systems (culture bags, etc.)
- The Cocoon’s integrated magnetic separation capabilities
Dr Matthew Hewitt, Head of Clinical Development, Personalized Medicine (PerMed) Initiative, Lonza
Matthew Hewitt is currently the Head of Clinical Development for the Personalized Medicine (PerMed) Initiative within Lonza. The PerMed Initiative has a cell and gene therapy focus working to alleviate pain-points in commercializing cell therapies. One of Matt’s responsibilities is the Cocoon Platform, a closed, automated, scalable cell therapy manufacturing platform which relieves many cell therapy manufacturing difficulties. Prior to joining Lonza, Matt led the Tumor Immunology and Microenvironment program at Bellicum Pharmaceuticals which concentrated on improving cell therapy efficacy in solid tumors. Matt led the Immunology group at the University of Pennsylvania’s Gene Therapy Program under Dr. James Wilson managing numerous AAV gene therapy programs. Matt received his Ph.D. in Biophysics & Physiology from the University of Alabama at Birmingham and completed his post-doctoral fellowship at Johns Hopkins University.